Duke Energy Corp vs Viatris Inc — how do they compare? Duke Energy Corp trades at $116.57 (market cap $91.10B), while Viatris Inc trades at $17.62 (market cap $20.03B). The key difference: Duke Energy Corp is far larger — about 4.5× Viatris Inc's market cap, and Duke Energy Corp pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 74 Days and Viatris Inc for 57 Days on average.
| DUK | VTRS | |
|---|---|---|
Market Cap | $91.10B | $20.03B |
Volume | 4,199,050 | 14,109,977 |
Sector | Utilities | Health |
52-Week High | $133.46 | $18.27 |
52-Week Low | $113.23 | $9.74 |
Typical Hold Time | 74 Days | 57 Days |
Enterprise Value | $183.61B | $32.15B |
Dividend Yield | 3.71% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $116.55, up 0.91% today, with a bullish technical signal despite mixed moving averages. The company shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding the $1.30 estimate. Revenue grew to $32.24B in 2025, and net income margin improved to 15.78%. Recent news highlights dividend declarations and data center growth opportunities, though rising Treasury yields pose a headwind for utility stocks.
DUK offers a stable dividend and benefits from data center demand, but high debt levels and interest rate sensitivity present risks. Analyst consensus is a Buy with a $134.44 price target, implying 15% upside. The stock's valuation is reasonable with a P/E of 17.6, supporting a cautious bullish outlook amid macroeconomic pressures.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
Latest headlines on both assets
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →